Author Profile

Jonathan Burlison, PhD

Patient Safety Project manager

Jonathan Burlison, Ph.D., is the Patient Safety Project manager in the Pharmaceutical Sciences Department at St. Jude Children’s Research Hospital.

Stories by Jonathan Burlison

New algorithm could help us better understand cancer at its genetic level
New algorithm could help us better understand cancer at its genetic level
Research

New algorithm could help us better understand cancer at its genetic level

Xiang Chen, PhD

This new cancer algorithm shows possible precision options for cancer treatment.

Apoptosis-causing protein is an intracellular lone wolf
Apoptosis-causing protein is an intracellular lone wolf
Research

Cancer-fighting ninja protein may offer clue to create self-harming cancer cells

Tudor Moldoveanu, PhD

This shape-shifting cipher of the cell may hold the key to curing cancer through causing cancer cells to kill themselves.

Influenza virus: Will Mother Nature deal us a deadly hand?
Influenza virus: Will Mother Nature deal us a deadly hand?
Research

Will Mother Nature deal a deadly hand with influenza virus?

Robert Webster, PhD

How close are we to another deadly influenza virus pandemic? Read about how scientists are figuring out how to prevent the next catastrophe.

Community HIV partnership reaches out for education and prevention
Community HIV partnership reaches out for education and prevention
Outreach

St. Jude community partnership highlighted during World AIDS Day

Andrea Stubbs

Read how St. Jude is reaching out to youth for HIV education and prevention, including a clinical trial for an HIV prevention and treatment drug.

Chronic Pain in Survivors of Childhood Cancer
Chronic Pain in Survivors of Childhood Cancer
Clinical

Chronic pain in survivors: How we can better understand an under-studied problem

Nicole Alberts, PhD

A new model explains key factors in chronic pain development, and future pain research designed to answer overlooked questions

LOXO-101 effective against tumors with rare NTRK gene fusion
LOXO-101 effective against tumors with rare NTRK gene fusion
Research

Targeted therapy larotrectinib could make tumors with rare NTRK fusion genes less lethal

Alberto Pappo, MD

Newly approved Vitrakvi (larotrectinib) scored high patient response rates by inhibiting a rare chromosomal abnormality that drives tumor growth.

Taking STEPS to improve genome-wide association studies
Taking STEPS to improve genome-wide association studies
Research

What is extreme phenotype sequencing? Taking STEPS to improve genome-wide association studies

Guolian Kang, PhD

Will a new genome sequencing data mining technique reveal the mother lode of secrets for treating cancer and other catastrophic diseases?

St. Jude and WHO collaborate to improve cancer cure rates
St. Jude and WHO collaborate to improve cancer cure rates
Outreach

St. Jude and WHO collaborate to improve cancer cure rate

Lance Wiedower

Learn how St. Jude and World Health Organization are taking on the six most common childhood cancers to improve global survival rates.

What is causing resistance to the new flu drug, Xofluza?
What is causing resistance to the new flu drug, Xofluza?
Research

What is causing resistance to the new flu drug, Xofluza?

Lee Morgan

A recently discovered mutation that occurs when the flu virus is exposed Xofluza could also cause drug resistance.

You can help prevent suicide
You can help prevent suicide
Clinical

You can help prevent suicide

Jennifer Harman, PhD

Suicidal thoughts or actions are not the end – don’t believe these myths associated with suicide.